Literature DB >> 2161485

Spread of herpes simplex virus type 1 in the central nervous system during experimentally reactivated encephalitis.

W G Stroop1, R R McKendall, E J Battles, D C Schaefer, B Jones.   

Abstract

Because many of the features of reactivated herpes simplex virus type 1 (HSV-1) central nervous systems (CNS) infections in vivo are incompletely understood, we used an animal model to study the development of the morphological, ultrastructural, radiological and immunological changes which occurred during acute and experimentally reactivated diseases. Rabbits were intranasally inoculated with HSV-1, and their latent trigeminal ganglionic and CNS infections were reactivated by intravenous injection of cyclophosphamide and dexamethasone. Technetium brain scans were performed to localize areas of blood-brain barrier breakdown, and cerebrospinal fluid (CSF) was analysed for IgG content by radial immunodiffusion assays. Nervous system tissues were studied by in situ hybridization and by immunofluorescent, light and electron microscopic techniques. Diffuse uptake of technetium was observed as HSV-1 spread transsynaptically into the brain during the acute phase of infection, and viral antigens and nucleic acids were detected in both the CNS olfactory and trigeminal systems. During latency, viral RNA was detected in the nuclei of neurons within the CNS olfactory cerebral and entorhinal cortices, indicating that HSV-1 became latent within the same CNS structures that were involved during the acute phase of infection. Following drug-induced reactivation, the brain scans revealed a more focal breakdown of the blood-brain barrier, and both neurons and neuronal processes in the entorhinal and olfactory cortices contained viral nucleic acids which correlated with the ultrastructural presence of HSV-1 virions. During the reactivated phase of infection a marked increase in the CSF IgG index occurred without an increase in the CSF: serum albumen ratio indicating a prompt intrathecal response in infected rabbits as compared to controls. To some extent, the CSF IgG index reflected the degree of histopathological damage.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161485     DOI: 10.1016/0882-4010(90)90076-3

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  7 in total

1.  Recurrent herpes labialis as a potential risk factor for nonarteritic anterior ischemic optic neuropathy.

Authors:  L N Johnson; G B Krohel; S D Allen; R Mozayeni
Journal:  J Natl Med Assoc       Date:  1996-06       Impact factor: 1.798

2.  Resident T Cells Are Unable To Control Herpes Simplex Virus-1 Activity in the Brain Ependymal Region during Latency.

Authors:  Chandra M Menendez; Jeremy K Jinkins; Daniel J J Carr
Journal:  J Immunol       Date:  2016-06-29       Impact factor: 5.422

3.  Relapse of herpes simplex virus encephalitis after surgical treatment for temporal lobe epilepsy: rare complication of epilepsy surgery.

Authors:  Takehiro Uda; Reiji Koide; Hirotaka Ito; Atsushi Hosono; Shigeki Sunaga; Michiharu Morino
Journal:  J Neurol       Date:  2012-11-30       Impact factor: 4.849

4.  Herpes simplex virus type 1 strain KOS-63 does not cause acute or recurrent ocular disease and does not reactivate ganglionic latency in vivo.

Authors:  W G Stroop; M C Banks
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 5.  Mechanisms of Blood-Brain Barrier Disruption in Herpes Simplex Encephalitis.

Authors:  Hui Liu; Ke Qiu; Qiang He; Qiang Lei; Wei Lu
Journal:  J Neuroimmune Pharmacol       Date:  2018-11-19       Impact factor: 4.147

6.  The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system.

Authors:  K Felgenhauer; H Reiber
Journal:  Clin Investig       Date:  1992-01

7.  Cloning and restriction endonuclease mapping of herpes simplex virus type-1 strains H129 and +GC.

Authors:  T E Kienzle; J S Henkel; J Y Ling; M C Banks; D R Beers; B Jones; W G Stroop
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.